Momentum Biotechnologies

Last November, the small-molecule inhibitor Revuforj (revumenib), from Syndax Pharmaceuticals, was approved by the FDA for the treatment of relapsed and refractory acute leukemias in adult and pediatric patients harboring a KMT2A translocation. In clinical trials, revumenib treatment was shown to increase remission rates in patients with KMT2A-rearranged acute leukemia. Recent evidence suggests that combination treatment with revumenib and tamibarotene may have synergistic effects, while alternative menin inhibitors continue to be explored and developed.?? ?? ?? To learn more about this and other exciting small-molecule drugs recently approved by the FDA, check out our blog post at: https://lnkd.in/dnMF2pjB? ?? ?? Or connect with our scientific team to explore how Momentum can accelerate your drug discovery and development research at: https://lnkd.in/dSD6dHDZ? ?? #DrugDiscovery #DrugDevelopment #Pharma #Revuforj #Revumenib?

Together, Momentum Biotechnologies and OmicScouts empower life science companies to push their drug discovery research forward with an unequaled combination of high-throughput screening and state-of-the-art proteomics.? ? Hear from company founders Can Ozbal and Hannes Hahne as they explain how the powerful synergy between these two expert teams opens a world of exciting scientific possibilities for new and existing clients.? ? To schedule a meeting with our now-expanded scientific team, send us a message at:?https://lnkd.in/dSD6dHDZ ? #DrugDiscovery #Biotech #Biopharma #Innovation

At Momentum, we rely on a wide range of state-of-the-art instruments to support our screening and proteomic workflows. These technologies enable us to process client samples rapidly and accurately, providing maximum results with minimum turnaround time!? ?? One of our workhorse platforms (shown here) is the Orbitrap Ascend mass spectrometer from Thermo Fisher Scientific. The Ascend leverages an innovative Tribrid architecture – integrating advanced quadrupole technology, an ultra-high field Orbitrap mass analyzer, and a dual-pressure linear ion trap – that enables our scientific team to characterize complex samples with ease. This powerful, flexible platform offers highly accurate peptide quantification and protein identification to facilitate high-throughput analysis of otherwise challenging targets and achieve drug discovery goals.?? ?? To learn more about how our team can use this platform (and many others) to advance your drug discovery research, connect with us at momentum.bio/contact? ?? #MassSpectrometry #MassSpec #Proteomics #DrugDiscovery?

Many thanks to the OmicScouts team for the warm welcome as we begin the process of integrating these two dedicated scientific teams. We look forward to an exciting future together! ????

Verona Pharma's Ohtuvayre (ensifentrine) was approved by the FDA in June 2024 for the treatment of chronic obstructive pulmonary disease (COPD). This small-molecule drug exerts both bronchoprotective and anti-inflammatory effects by inhibiting two phosphodiesterases (PDE3 and PDE4). Recent research indicates that ensifentrine can also effectively reduce MRSA-induced lung inflammation, suggesting that the drug may become indicated for an expanded range of lung-related diseases in the years to come.?? ?? ?? To learn more about this and other exciting small-molecule drugs recently approved by the FDA, check out our blog post at: https://lnkd.in/dnMF2pjB? ?? ?? Or connect with our scientific team to explore how Momentum can accelerate your drug discovery and development research at: https://lnkd.in/dSD6dHDZ? ?? #DrugDiscovery #DrugDevelopment #Pharma #Ohtuvayre #Ensifentrine?

We are excited to announce that Momentum Biotechnologies has acquired?OmicScouts, a premier proteomic service provider based in Munich, Germany!??Our customers will now have access to OmicScouts' extensive collection of powerful proteomic assays to advance their drug discovery programs. The integrated team will continue our tradition of excellent service and deep scientific expertise while now offering end-to-end pipelines to take research projects from hit discovery through a full suite of follow-up and characterization services, including proteomics and chemoproteomics.?? ? We look forward to sharing more details about this exciting development as we continue to integrate our teams and enhance our collective capabilities! ? Read the full press release at our website:?https://momentum.bio ? Or, to schedule a conversation about how our new experimental capabilities and extended service pipeline could benefit your research program, send us a message at?https://lnkd.in/dSD6dHDZ?or reach out to your personal contact at Momentum. #DrugDiscovery #Innovation #Proteomics #Biopharma #Pharma

In April 2024, X4 Pharmaceuticals saw XOLREMDI (mavorixafor) become the first drug approved by the FDA for the treatment of WHIM syndrome, an inherited immunodeficiency caused by mutations in the chemokine receptor CXCR4. Mavorixafor alleviates overactive signaling to restore immune homeostasis, reducing infection frequency, severity, and duration in WHIM patients. Mavorixafor has also shown potential as a treatment for neurodegenerative diseases and for several cancers, including melanoma.? ?? ?? To learn more about this and other exciting small-molecule drugs recently approved by the FDA, check out our blog post at: https://lnkd.in/dnMF2pjB? ?? ?? Or connect with our scientific team to explore how Momentum can accelerate your drug discovery and development research at: https://lnkd.in/dSD6dHDZ? ?? #DrugDiscovery #DrugDevelopment #Pharma #XOLREMDI #Mavorixafor?

???Join the?Momentum team!??? ? At Momentum, we are rapidly scaling our business and service offerings and are seeking a high-performing professional to be Director of Business Development. The Director of Business Development will drive Momentum’s business development and commercial goals, including crafting and executing against various strategic initiatives to win new customers and grow relationships with existing customers.? ? Apply at:?https://lnkd.in/efcKaR8z ? Or send a résumé or CV by email to [email protected] with the subject line?Director of Business Development. ? #Hiring #BusinessDevelopment #Biotech?

March 2024 saw the FDA approval of Italfarmaco S.p.A.'s Duvyzat (givinostat), the first non-steroidal drug for the treatment of Duchenne muscular dystrophy (DMD). This orally active small molecule is a histone deacetylase (HDAC) inhibitor shown to delay progression of muscle weakness in ambulant DMD patients. Additional clinical applications continue to be explored, as well as novel approaches for the delivery and targeting of these powerful therapeutics.??? ?? ?? To learn more about this and other exciting small-molecule drugs recently approved by the FDA, check out our blog post at: https://lnkd.in/dnMF2pjB? ?? ?? Or connect with our scientific team to explore how Momentum can accelerate your drug discovery and development research at: https://lnkd.in/dSD6dHDZ? ?? #DrugDiscovery #DrugDevelopment #Pharma #Duvyzat #Givinostat?

In March 2024, Madrigal Pharmaceuticals saw the approval of Rezdiffra (resmetirom) for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring. This small-molecule drug targets the thyroid hormone receptor THR-β and has been shown to improve a number of liver biomarkers. Excitingly, resmetirom represents the first direct treatment option for NASH patients with significant liver fibrosis, and additional studies seek to explore its efficacy in the treatment of other hepatic conditions.?? ?? ?? To learn more about this and other exciting small-molecule drugs recently approved by the FDA, check out our blog post at: https://lnkd.in/dnMF2pjB? ?? ?? Or connect with our scientific team to explore how Momentum can accelerate your drug discovery and development research at: https://lnkd.in/dSD6dHDZ? ?? #DrugDiscovery #DrugDevelopment #Pharma #Rezdiffra #Resmitirom?